{"name":"yuanli Zhao","slug":"yuanli-zhao","ticker":"","exchange":"","domain":"","description":"Yuanli Zhao is a pharmaceutical company focused on the research and development of innovative therapies. The company's lead product, dl-3-n-butylphthalide (NBP), is in Phase 3 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"dl-3-n-butylphthalide (NBP)","genericName":"dl-3-n-butylphthalide (NBP)","slug":"dl-3-n-butylphthalide-nbp","indication":"Ischemic stroke","status":"phase_3"}]}],"pipeline":[{"name":"dl-3-n-butylphthalide (NBP)","genericName":"dl-3-n-butylphthalide (NBP)","slug":"dl-3-n-butylphthalide-nbp","phase":"phase_3","mechanism":"DL-3-n-butylphthalide (NBP) is a small molecule that acts as a vasodilator and neuroprotective agent.","indications":["Ischemic stroke","Cerebral ischemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9rZmRXenJTNFJjS2hhV2d6d0s1ZzJ2RnF1em8tVzg1VkdJQVp2RHQ4a2JDLWNKTmFkNnEwQ3NxOEdHWUNwR1JBZjZ0QzQzYTRoWWV2d05rTEtXRDJ0UTdv?oc=5","date":"2018-06-14","type":"pipeline","source":"Nature","summary":"NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice - Nature","headline":"NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}